Dataset Viewer
Auto-converted to Parquet Duplicate
NCT ID
stringlengths
11
11
Brief Title
stringlengths
18
300
Official Title
stringlengths
26
590
Organization
stringlengths
3
107
Overall Status
stringclasses
1 value
Start Date
stringlengths
7
10
Completion Date
stringlengths
7
10
Study Type
stringclasses
1 value
Phases
stringclasses
1 value
Enrollment Count
int64
1
358k
Conditions
stringlengths
3
1.22k
Keywords
stringlengths
2
750
Eligibility Criteria (registry)
stringlengths
67
17.4k
Sex
stringclasses
3 values
Minimum Age
stringclasses
79 values
Maximum Age
stringclasses
119 values
Brief Summary
stringlengths
38
4.86k
Protocol Doc Count
int64
1
6
Protocol Filenames
stringclasses
45 values
Protocol URLs
stringlengths
69
424
SNOMED CT
stringlengths
4
82
primary_therapeutic_area
stringclasses
22 values
complete eligibility criteria
stringlengths
174
23.3k
Acronym
stringlengths
2
14
Primary Completion Date
stringlengths
7
10
Intervention Model
stringclasses
5 values
Primary Purpose
stringclasses
9 values
Masking
stringclasses
5 values
Arms
stringlengths
1
1.27k
Interventions
stringlengths
14
3.84k
Primary Outcomes
stringlengths
28
64.1k
Secondary Outcomes
stringlengths
33
185k
Healthy Volunteers
bool
2 classes
Standard Ages
stringclasses
6 values
Detailed Description
stringlengths
8
26.5k
NCT03683030
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR)
Biosense Webster, Inc.
COMPLETED
2018-10-22
2022-02-18
INTERVENTIONAL
PHASE3
397
Atrial Fibrillation
Interventional, Radiofrequency Ablation, Paroxysmal Atrial Fibrillation
Key Inclusion Criteria: * Diagnosed with Symptomatic Paroxysmal Atrial Fibrillation. 1. At least two symptomatic AF episodes within last six months from enrollment. 2. At least one ectrocardiographically documented AF episode within twelve (12) months prior to enrollment. * Failed at least one Class I or Class II...
ALL
18 Years
75 Years
The primary objective of this clinical investigation is to demonstrate safety and effectiveness of the Multi-Electrode RF Balloon catheter for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation.
1
Prot_004.pdf
https://cdn.clinicaltrials.gov/large-docs/30/NCT03683030/Prot_004.pdf
Atrial fibrillation
Cardiology
Inclusion Criteria: - Diagnosed with Symptomatic PAF (Physician’s note indicating recurrent self-terminating AF). - At least two (2) symptomatic AF episodes within last six (6) months from enrollment. - At least one (1) electrocardiographically documented AF episode within twelve (12) months prior to enrollment. Electr...
STELLAR
2022-02-18
SINGLE_GROUP
TREATMENT
NONE
Treatment Group
DEVICE: Multi-Electrode RF Balloon Catheter (Multi-Electrode RF Balloon Catheter will be inserted)
Number of Participants With Any Primary Adverse Events (PAE) That Occurred Within 7 Days Following Atrial Fibrillation (AF) Ablation Procedure Using HELIOSTAR Catheter: An AE is any untoward medical occurrence in a participant whether or not related to the investigational medical device. PAEs included myocardial infarc...
Percentage of Participants With Acute Procedural Success: Acute procedural success is defined as confirmation of entrance block in clinically relevant pulmonary veins (PVs) (all PVs except those that were silent and/or could not be cannulated) after adenosine and/or isoproterenol challenge (with or without the use of a...
false
ADULT, OLDER_ADULT
The STELLAR study is a pivotal, prospective, multicenter, single-arm, clinical evaluation of the Multi-Electrode RF Balloon catheter. The study will evaluate the safety and effectiveness of the Multi-Electrode RF Balloon catheter used for ablation in patients with paroxysmal atrial fibrillation (PAF).
NCT02725567
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
Vertex Pharmaceuticals Incorporated
COMPLETED
2016-06-02
2022-06-28
INTERVENTIONAL
PHASE3
57
Cystic Fibrosis
null
Inclusion Criteria: * Confirmed diagnosis of CF by sweat chloride value or CF mutation criteria. * Have 1 of the following 10 CFTR mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D or R117H (eligible in regions where ivacaftor is approved for use). Part A/B group may als...
ALL
1 Month
24 Months
The purpose of this study was to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in participants with cystic fibrosis (CF) who are \<24 months of age at treatment initiation and have an ivacaftor-responsive CF transmembrane conductance regulator (CFTR) gene mutation.
1
Prot_000.pdf
https://cdn.clinicaltrials.gov/large-docs/67/NCT02725567/Prot_000.pdf
Cystic fibrosis
Pulmonology
Inclusion Criteria: - Male or female with confirmed diagnosis of CF, defined as a sweat chloride value ≥60 mmol/L by quantitative pilocarpine iontophoresis OR 2 CF-causing mutations. - A sweat chloride test must be performed if the sweat chloride value is not available in the subject’s medical records and the value is ...
null
2022-06-28
PARALLEL
TREATMENT
NONE
Part A: 3 to <24 months; Part B + A/B:1 to < 24 months
DRUG: IVA (Granules in sachet for oral administration.)
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs): (Day 1 through Day 70); Part A: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA): (Pre-dose, 2-4 hours, 6-8 hours, 24-60 hours post-dose); Part B +A/B...
Part B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA): (Week 2 (pre-dose, 2-4 hours, 6-8 hours post-dose); Week 8 (pre-dose,1 hour, 4-hour post-dose); Week 24 (pre-dose, 2-4 hours post dose)); Part B + A/B: Absolute Change From Baseline in Sweat Chloride: Sweat samples were collected u...
false
CHILD
null
NCT02135692
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects With a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
GlaxoSmithKline
COMPLETED
2014-05-29
2017-10-05
INTERVENTIONAL
PHASE3
339
Asthma
Severe eosinophilic asthma, Extension study, Expanded access, Safety, Mepolizumab, Eosinophils
Inclusion Criteria: * Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent. * Male or Eligible Female Subjects: To be eligible for the study, females of child-bearing potential must commit to consistent and correct use of an acceptabl...
ALL
12 Years
null
This is a multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma. This study will enroll a subset of subjects from Study MEA115661 who have demonstrated clear benefit from therapy and who without ...
1
Prot_000.pdf
https://cdn.clinicaltrials.gov/large-docs/92/NCT02135692/Prot_000.pdf
Asthma
Pulmonology
Inclusion Criteria: - Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent. - Male or Eligible Female Subjects: To be eligible for the study, females of child-bearing potential must commit to consistent and correct use of an acceptable...
null
2017-10-05
SINGLE_GROUP
TREATMENT
NONE
Mepolizumab 100 mg
BIOLOGICAL: Mepolizumab (Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.); DRUG: SOC (Standard of Care (SOC) will differ by participant, however it will generally include oral...
Annualized Rate of On-treatment Exacerbations Per Year: Exacerbations are defined as the worsening of asthma which requires use of systemic corticosteroids intravenous (IV) or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic ...
Mean Change From Baseline in Asthma Control Questionnaire (ACQ)-5 On-treatment Score: The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma control. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitatio...
false
CHILD, ADULT, OLDER_ADULT
null
NCT02491671
Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection
Prospective, Multicenter, Open-Label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak After Lung Resection in High-risk Patients, Applying HEMOPATCH®
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
COMPLETED
2015-11-24
2019-06-30
INTERVENTIONAL
PHASE3
260
Prolonged Air Leak, Lung Resection
Prevention PAL Prolonged Air Leak (PAL), Lung Resection, Thoracic Surgery, Post-operative Thoracic Air Leak
Inclusion Criteria: * Scheduled anatomical lung resection indicated for any non-infectious disease (excluding Pneumonectomy) * Patients classified in class D according estimated risk of PAL * Age between 18 and 80 years Exclusion Criteria: * Those patients that according to Investigator assessment are not going to t...
ALL
18 Years
80 Years
The effectiveness of tissue sealants to prevent Prolonged Air Leak (PAL) after lung resection procedures remains unproved. The investigators hypothesize that one of the main reasons for that is the heterogeneity of previously studied populations. Since currently the risk of postoperative PAL can be scored with a reason...
1
Prot_SAP_000.pdf
https://cdn.clinicaltrials.gov/large-docs/71/NCT02491671/Prot_SAP_000.pdf
Prolonged air leak
Pulmonology
Inclusion Criteria: - Age between 18 and 80 years - Patients who are going to undergo scheduled anatomical lung resection (excluding pneumonectomy). - Patients class D on the air leak risk scale. Exclusion Criteria: - Those who in the judgment of the investigator are not in an adequate situation to tolerate the proced...
null
2019-06-30
PARALLEL
PREVENTION
NONE
Experimental group; Control group
DEVICE: Hemopatch (); PROCEDURE: standard preventive measures ()
Number of Participants With Prolonged Air Leak (PAL): Prevalence of Prolonged Air Leak (PAL) measured as binary variable (YES/NO) and recorded, from day of surgery to the fifth postoperative day, in the study questionnaire. The occurrence of the outcome will be recorded if air leak exists 5 days or more after surgery (...
Duration of Air Leaks: Measured as continuous variable (days) and recorded, from day of surgery to the day of withdraw the chest tube. (standardized criteria for pulling out chest drainage/s will be agreed among investigators) (Check everyday from day of surgery up to 38 days post-operative at maximum); Number of Parti...
false
ADULT, OLDER_ADULT
null
NCT04186819
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer
Blue Earth Diagnostics
COMPLETED
2020-03-02
2021-06-21
INTERVENTIONAL
PHASE3
356
Prostate Cancer
Primary Prostate Cancer, Diagnostic, Prostate Specific Membrane Antigen (PSMA), Positron Emission Tomography (PET) Scan
Inclusion Criteria: 1. Patient is male and aged \>18 years old. 2. Histologically confirmed adenocarcinoma of the prostate. 3. Patients electing to undergo Radical Prostatectomy (RP) with Pelvic lymph node dissection (PLND). Exclusion Criteria: 1. Patients who are planned to have an x-ray contrast agent or other PET...
MALE
18 Years
null
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.
1
Prot_000.pdf
https://cdn.clinicaltrials.gov/large-docs/19/NCT04186819/Prot_000.pdf
Prostate cancer
Oncology
Inclusion Criteria: - Patient willing to provide signed informed consent and willing to comply with all required study schedule events, where safe and feasible. - Patient is male and aged >18 years old. - Histologically confirmed adenocarcinoma of the prostate. - Candidate for RP with PLND and scheduled to undergo the ...
null
2021-06-21
SINGLE_GROUP
DIAGNOSTIC
NONE
Patients
DRUG: rhPSMA-7.3 (18F) Injection (Radioligand for PET CT scanning); DIAGNOSTIC_TEST: Positron Emission Tomography scan (imaging test with radioligand)
Specificity: The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND. (Convent...
Verified Detection Rate (VDR) for M1 Lesions - Percentage of Patients in Whom rhPSMA-7.3 (18F) Imaging Detected at Least One Verified M1 Metastasis, as Determined by Central BIE and Confirmed by SoT (Biopsy or Imaging) (Objective 1): This was a key secondary endpoint in this study and included patients in the EEP with ...
false
ADULT, OLDER_ADULT
Main objective is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central blinded image evaluation \[BIE\]) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during radical prostatectomy (RP...
NCT04115319
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.
COMPLETED
2019-11-21
2022-12-30
INTERVENTIONAL
PHASE3
305
Schizophrenia
schizophrenia
Inclusion criteria: The main inclusion criteria include, but are not limited to the following: * Male or female participant between 18 to 65 years of age (inclusive) at the time of consent. * Participant meets DSM-5 criteria for a diagnosis of schizophrenia as established by clinical interview at screening (using the...
ALL
18 Years
65 Years
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers ...
1
Prot_000.pdf
https://cdn.clinicaltrials.gov/large-docs/19/NCT04115319/Prot_000.pdf
Schizophrenia
Psychiatry
Inclusion Criteria: - Subject must give written informed consent and privacy authorization prior to participation in the study. Separate consent will be obtained from a caregiver or legal guardian if required by local law. - In the Investigator’s opinion, the subject is appropriate for this study and is willing and abl...
null
2022-12-30
PARALLEL
TREATMENT
QUADRUPLE
SEP363856; quetiapine XR
DRUG: SEP363856 (SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule); DRUG: quetiapine XR (quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule)
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation: An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Untoward medical occurrences that occured after first...
null
false
ADULT, OLDER_ADULT
This is a 52-week, multicenter, randomized, double-blind, parallel-group, flexible-dose study designed to evaluate the long-term safety and tolerability of SEP-363856 (50 to 100 mg/day) compared with quetiapine XR (400 to 800 mg/day) in clinically stable adult participants with schizophrenia. This study is projected to...
NCT03129100
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Eli Lilly and Company
COMPLETED
2017-05-09
2021-05-27
INTERVENTIONAL
PHASE3
773
Axial Spondyloarthritis
null
Inclusion Criteria: * Have completed the final study visit in Study RHBV (NCT02696785), RHBW (NCT02696798), or RHBX (NCT02757352). (Note: Participants from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a tumor necrosis factor \[TNF\] inhibitor). * Must agree to use a reli...
ALL
18 Years
null
The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
1
Prot_000.pdf
https://cdn.clinicaltrials.gov/large-docs/00/NCT03129100/Prot_000.pdf
Axial spondyloarthritis
Rheumatology
Inclusion Criteria: - Have completed the final study visit in Study RHBV, RHBW, or RHBX. (Note: Patients from Study RHBX are not eligible if they permanently discontinued ixekizumab and were receiving a TNF inhibitor). - Must agree to use a reliable method of birth control. - If the patient is male, the patient must ag...
null
2020-05-26
PARALLEL
TREATMENT
TRIPLE
Ixekizumab (IXE) 80Q4W; Ixekizumab (IXE) 80Q2W; Placebo
DRUG: Ixekizumab (Administered SC); DRUG: Placebo (Administered SC)
Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment): A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters us...
Percentage of Participants Who do Not Experience a Flare: A flare is defined as Ankylosing Spondylitis Disease Activity Score (ASDAS ≥2.1) at 2 consecutive visits, or ASDAS \>3.5 at any visit during Period 2. ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with high sens...
false
ADULT, OLDER_ADULT
null
NCT03198507
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection
RedHill Biopharma Limited
COMPLETED
2017-06-18
2018-12-13
INTERVENTIONAL
PHASE3
455
Helicobacter Pylori Infection, Dyspepsia
null
Inclusion Criteria: 1. Be ages 18 - 70, inclusive; non-Asian males and females (This population has been demonstrated to have significantly elevated omeprazole levels as per the prescriber information for other omeprazole products). A person having origins in any of the original peoples of the Far East, Southeast Asia...
ALL
18 Years
70 Years
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients against an active comparator.
1
Prot_002.pdf
https://cdn.clinicaltrials.gov/large-docs/07/NCT03198507/Prot_002.pdf
Helicobacter pylori infection
Pulmonology
Inclusion Criteria: - Be ages 18 – 70, inclusive; non-Asian males and females (This population has been demonstrated to have significantly elevated omeprazole levels as per the prescriber information for other omeprazole products). A person having origins in any of the original peoples of the Far East, Southeast Asia, ...
ERADICATE Hp2
2018-10-24
PARALLEL
TREATMENT
TRIPLE
RHB-105; Active Comparator
DRUG: RHB-105 (The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of: * Rifabutin 150 mg * Amoxicillin 3000 mg * Omeprazole 120 mg One 50mg Riboflavin tablet to be taken once daily to maintain the blind....
Number of Participants With Eradication of H. Pylori: Eradication of H. pylori confirmed via 13C Urea Breath Test (UBT) testing. Subjects with negative test results (eradication of H. pylori) were considered treatment successes. Subjects who tested positive for H. pylori infection (no eradication) were considered treat...
Number of Participants With H. Pylori Cultures That Presented Antibiotic Resistance and Susceptibility: The primary endpoint was summarized within subgroups formed by the presence of H. pylori susceptibility and resistance to amoxicillin, clarithromycin, metronidazole, and rifabutin from H. pylori cultures from samples...
false
ADULT, OLDER_ADULT
This is a, randomized, double blind, active comparator-controlled study of RHB-105 in adult subjects complaining of epigastric discomfort that have been screened and found to be positive for H. pylori infection via 13C UBT and gastric biopsy. The biopsy samples will also be used to conduct H. pylori antibiotic suscept...
NCT03050307
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection
Takeda
COMPLETED
2017-04-17
2020-05-26
INTERVENTIONAL
PHASE3
234
Gastric Ulcer
Drug therapy
Inclusion Criteria: 1\. Has endoscopic evidence of active gastric ulcer(s) (i.e. mucosal defects with white coating \[including cases associated with blood coagula as long as there is no active bleeding\]) measuring 5 mm or larger in longest diameter within 14 days prior to randomization. Exclusion Criteria: 1. Has ...
ALL
18 Years
null
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer.
1
Prot_000.pdf
https://cdn.clinicaltrials.gov/large-docs/07/NCT03050307/Prot_000.pdf
Gastric ulcer
Gastroenterology
Inclusion Criteria: - In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements. - The subject or, when applicable, the subject’s legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to ...
null
2020-02-19
PARALLEL
TREATMENT
QUADRUPLE
TAK-438 20 mg; Lansoprazole 30 mg
DRUG: TAK-438 (TAK-438 tablets); DRUG: Lansoprazole (Lansoprazole capsules); DRUG: TAK-438 Placebo (TAK-438 placebo-matching tablets); DRUG: Lansoprazole Placebo (Lansoprazole placebo-matching capsules); DRUG: Bismuth-Containing Quadruple Therapy (1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citr...
Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8: Endoscopic healing was defined as the disappearance of all white coats associated with GUs confirmed endoscopically. (Week 4 or 8)
Percentage of Helicobacter Pylori Infected (HP+) Participants With Successful HP Eradication After 4 or 8 Weeks of Treatment: HP infection status was determined by 13C-UBT. The urea breath test is used to detect infection with HP, a bacteria associated with stomach ulcers, by testing individual breath samples in a cent...
false
ADULT, OLDER_ADULT
The drug being tested in this study is called TAK-438. TAK-438 is being tested to treat people who have stomach ulcers and also may or may not have Helicobacter pylori (HP) infection. This study will look at stomach ulcer healing and also the elimination of HP in people who take TAK-438 versus lansoprazole. The study ...
NCT03084471
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
AstraZeneca
COMPLETED
2017-06-05
2022-12-16
INTERVENTIONAL
PHASE3
867
Advanced Solid Malignancies
Programmed death ligand 1 (PD-L1), Cytotoxic T-lymphocyte antigen-4 (CTLA-4), Durvalumab in combination with tremelimumab
Inclusion criteria: 1. Must have a life expectancy of at least 12 weeks. 2. Age ≥18 years at the time of screening. For patients aged \<20 years and enrolled in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative 3. Capable of giving signed informed co...
ALL
18 Years
130 Years
To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.
1
Prot_002.pdf
https://cdn.clinicaltrials.gov/large-docs/71/NCT03084471/Prot_002.pdf
Malignant neoplasm of solid organ
Oncology
Inclusion Criteria: - Must have a life expectancy of at least 12 weeks. - Age ≥18 years at the time of screening. For patients aged <20 years and enrolled in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative - Capable of giving signed informed consent...
STRONG
2020-03-31
SEQUENTIAL
TREATMENT
NONE
Combination therapy; Monotherapy
BIOLOGICAL: MEDI4736 (Durvalumab) (A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).); BIOLOGICAL: MEDI4736 (Durvalumab) + Tremelimumab (Durvalumab: A h...
Number of Participants With Adverse Events of Special Interest (AESIs): Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of AESIs were assessed. AESIs included events with a potential inflammatory or immune-mediated mechanism that required interventions such as steroids, immunosu...
Overall Survival: Overall survival was defined as the time from the first date of treatment until death due to any cause. (From screening to final data cutoff (maximum up to 4 years) following date of first patient treatment initiation.); Number of Participants With Adverse Events: Incidence, severity, nature, seriousn...
false
ADULT, OLDER_ADULT
This is an open-label, multi-center, study to determine the short and long term safety of fixed doses of durvalumab 1500 mg + tremelimumab 75 mg combination therapy or durvalumab 1500 mg monotherapy in patients with advanced solid malignancies. This study is modular in design, one or more of the modules will be opened ...
NCT00118209
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Alliance for Clinical Trials in Oncology
COMPLETED
2005-05
2021-11-15
INTERVENTIONAL
PHASE3
524
Large B Cell Lymphoma
null
1. Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease. * Stage I primary mediastinal (thymic) DLBCL is also eligible. * Patients with an underlying low-grade lymphoma, such as a transformed lymphoma or low-grade lymphoma in the bone marrow, are not eligible. * Diagnosis should be b...
ALL
18 Years
null
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting...
1
Prot_SAP_000.pdf
https://cdn.clinicaltrials.gov/large-docs/09/NCT00118209/Prot_SAP_000.pdf
Diffuse large B-cell lymphoma
Oncology
Inclusion Criteria: - Histologically documented de novo CD20+ DLBCL with stage II, III or IV disease. - Stage I primary mediastinal (thymic) DLBCL is also eligible. - Diagnosis should be based on an adequate tissue sample, including open biopsy or core needle biopsy. - Patients must have one of the following WHO [21] c...
null
2017-10
PARALLEL
TREATMENT
NONE
Arm A - R-CHOP; Arm B - DA-EPOCH-R
BIOLOGICAL: rituximab (IV); DRUG: cyclophosphamide (IV); DRUG: doxorubicin (IV or CIVI); DRUG: vincristine (IV or CIVI); DRUG: prednisone (oral); DRUG: etoposide (CIVI); DRUG: filgrastim (IV); DRUG: pegfilgrastim (IV)
Progression-Free Survival Rate at 2 and 5 Years: Progression-free survival (PFS) is defined as the time from randomization to progression, relapse, or death from any cause, whichever occurred first. Progression (PD) or Relapse\> * ≥ 50% increase from nadir in the SPD of any previously identified abnormal node for PRs ...
Response Rate: The overall response rate is defined as the percentage of participants with a response (Complete Response or Partial Response) (Up to 5 years post-registration); Overall Survival Rate at 2 and 5 Years: Overall survival is defined as the time from randomization to death due to any cause. The overall survi...
false
ADULT, OLDER_ADULT
PRIMARY OBJECTIVES: I. To compare the event-free survival of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone (R-CHOP) versus dose-adjusted (DA-) etoposide, prednisone, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, and rituximab (EPOCH-R) chemotherapy in untre...
NCT02480764
Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension
Takeda
COMPLETED
2015-08-27
2017-10-13
INTERVENTIONAL
PHASE3
612
Essential Hypertension
Drug therapy
Inclusion Criteria: 1. Is treated with antihypertensive therapy and has a post-washout mean sitting clinic systolic blood pressure (SBP) ≥150 and ≤180 mm Hg on Day 1; or the participant has not received antihypertensive treatment within 28 days prior to Screening and has a mean sitting clinic SBP ≥150 and ≤180 mm Hg a...
ALL
18 Years
null
The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension.
1
Prot_000.pdf
https://cdn.clinicaltrials.gov/large-docs/64/NCT02480764/Prot_000.pdf
Essential hypertension
Cardiology
Inclusion Criteria: - The subject is treated with antihypertensive therapy and has a post-washout mean sitting clinic SBP ≥150 and ≤180 mm Hg on Day 1; or the subject has not received antihypertensive treatment within 28 days prior to Screening and has a mean sitting clinic SBP ≥150 and ≤180 mm Hg at the Screening Visi...
null
2017-09-22
PARALLEL
TREATMENT
QUADRUPLE
Azilsartan medoxomil 40 mg; Azilsartan medoxomil 80 mg; Valsartan 160 mg
DRUG: Azilsartan medoxomil (Azilsartan medoxomil tablets); DRUG: Valsartan (Valsartan 80 mg capsules); DRUG: Azilsartan medoxomil Placebo (Azilsartan medoxomil placebo-matching tablets); DRUG: Valsartan Placebo (Valsartan placebo-matching capsules)
Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP): The change in trough clinic sitting SBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting SBP measurements. Blood pressure was measured using a validated, automated device a...
Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure (DBP): The change in trough clinic sitting DBP measured at Week 8 relative to baseline. The trough is the average of the non-missing values of 3 serial trough sitting DBP measurements. Blood pressure was measured using a validated, automated device ...
false
ADULT, OLDER_ADULT
The drug being tested in this study is called TAK-491 (azilsartan medoxomil). Azilsartan medoxomil is being tested to treat Chinese people who have essential hypertension. This study will look at change in blood pressure after 8 weeks of treatment in people who take azilsartan medoxomil compared to people who take vals...
End of preview. Expand in Data Studio

ProtocolEC

A protocol-derived benchmark for complete clinical-trial eligibility-criteria (EC) generation.

ProtocolEC pairs each of 4,302 completed Phase III trials (22 therapeutic areas) with (i) its ClinicalTrials.gov registry metadata and registry EC, and (ii) a more complete EC set extracted from the trial's protocol PDF. Protocol EC contain roughly twice the criteria and words of the registry EC. Splits are 80/10/10, stratified by therapeutic area.

Split Trials
train 3,443
validation 429
test 430

Task

Given a trial's features (title, summary, phase, conditions, interventions, demographics), generate the complete, protocol-level eligibility criteria (complete eligibility criteria). The registry EC (Eligibility Criteria (registry)) is a compressed public summary and serves as a baseline / comparison, not the target.

from datasets import load_dataset
ds = load_dataset("<your-org>/protocolec")
ex = ds["test"][0]
ex["Eligibility Criteria (registry)"]   # compressed registry summary (baseline)
ex["complete eligibility criteria"]     # protocol-extracted GOLD target

Columns (35)

  • Identifier: NCT ID
  • Target (gold): complete eligibility criteria — protocol-extracted complete EC
  • Registry EC (baseline): Eligibility Criteria (registry)
  • Trial features (input): Brief Title, Official Title, Brief Summary, Detailed Description, Phases, Conditions, Interventions, Intervention Model, Primary Purpose, Masking, Arms, Study Type, Keywords, SNOMED CT, primary_therapeutic_area, Enrollment Count, Overall Status, Organization, Acronym, Primary Outcomes, Secondary Outcomes, Start Date, Completion Date, Primary Completion Date
  • Demographics: Sex, Minimum Age, Maximum Age, Standard Ages, Healthy Volunteers
  • Provenance: Protocol Doc Count, Protocol Filenames, Protocol URLs

Protocol PDFs

The source protocol PDFs are not redistributed here. Each row carries Protocol URLs (ClinicalTrials.gov CDN links), from which the PDFs can be downloaded directly if needed.

Construction (summary)

Phase III trials with an attached protocol PDF were retrieved from the ClinicalTrials.gov v2 API; the EC section of each PDF was localized with a deterministic three-stage locator; EC were extracted verbatim with an LLM extractor; multiple protocol documents per trial were merged; each trial was assigned a primary therapeutic area; and a blinded three-judge audit validated coverage/enrichment against the registry EC. See the paper for full details.

License & ethics

Released for non-commercial research use (CC BY-NC 4.0). Source records are U.S. public-domain ClinicalTrials.gov content. The data contains no patient-level records or identifiable health information: eligibility criteria describe general study-population requirements, not individuals.

Citation

@article{protocolec,
  title  = {Beyond the Registry: A Protocol-Derived Dataset and Embedding-Guided Method for Complete Clinical Trial Eligibility Criteria Generation},
  author = {<authors>},
  year   = {2026}
}
Downloads last month
48